Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas

Experimental Hematology

Volumn 38, Issue 1, 2010, Pages 38-45

  Nagel, Sabine ^a,b   Hirschmann, Petra ^a   Dirnhofer, Stephan ^a   Günthert, Ursula ^a   Tzankov, Alexandar ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CD44V ANTIGEN; CD44V6 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; HYALURONIC ACID; HYALURONIC ACID BINDING PROTEIN; ISOPROTEIN; MYC PROTEIN; OSTEOPONTIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; GENE AMPLIFICATION; GENE TRANSLOCATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE C MYC; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TISSUE MICROARRAY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD44; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 71249122797     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.10.010     Document Type: Article

References (43)

1. Stein H., Warnke R., and Chan W. Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008), WHO Press, Lyon 233-237
2. de Leval L., and Harris N.L. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 43 (2003) 509-528
3. Lossos I.S. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 23 (2005) 6351-6357
4. Muris J.J., Meijer C.J., Vos W., et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 208 (2006) 714-723
5. Pileri S.A., Dirnhofer S., Went P., et al. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 41 (2002) 482-509
6. Rosenwald A., and Staudt L.M. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 44 Suppl 3 (2003) 41-47
7. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
8. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275-282
9. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 1937-1947
10. Shipp M.A., Harrison D.P., Anderson J.R., et al. A predictive model for aggressive NHL: The international non-Hodgkin's Lymphoma Prognostic Factor Project. N Engl J Med 329 (1993) 987-994
11. Drillenburg P., Wielenga V.J., Kramer M.H., et al. CD44 expression predicts disease outcome in localized large B cell lymphoma. Leukemia 13 (1999) 1448-1455
12. Horst E., Meijer C.J., Radaskiewicz T., et al. Expression of a human homing receptor (CD44) in lymphoid malignancies and related stages of lymphoid development. Leukemia 4 (1990) 383-389
13. Horst E., Meijer C.J., Radaszkiewicz T., Ossekoppele G.J., Van Krieken J.H., and Pals S.T. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 4 (1990) 595-599
14. Ponta H., Sherman L., and Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4 (2003) 33-45
15. Stauder R., and Günthert U. CD44 isoforms-impact on lymphocyte activation and differentiation. Immunologist 3 (1995) 78-83
16. Günthert U., and Johansson B. CD44-a protein family involved in autoimmune diseases and apoptosis. Immunologist 8 (2001) 106-109
17. Inagaki H., Banno S., Wakita A., Ueda R., and Eimoto T. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma. Mod Pathol 12 (1999) 546-552
18. Ristamaki R., Joensuu H., Soderstrom K.O., and Jalkanen S. CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis. J Pathol 176 (1995) 259-267
19. Salles G., Zain M., Jiang W.M., Boussiotis V.A., and Shipp M.A. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 82 (1993) 3539-3547
20. Stauder R., Eisterer W., Thaler J., and Günthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 85 (1995) 2885-2899
21. Terpe H.J., Koopmann R., Imhof B.A., and Günthert U. Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol 174 (1994) 89-100
22. Tzankov A., Pehrs A.C., Zimpfer A., et al. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 56 (2003) 747-752
23. Mielgo A., van Driel M., Bloem A., Landmann L., and Günthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 13 (2006) 465-477
24. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., and Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107 (2001) 1055-1061
25. Lin Y.H., and Yang-Yen H.F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276 (2001) 46024-46030
26. Hamilton S.R., Fard S.F., Paiwand F.F., et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 282 (2007) 16667-16680
27. Maxwell C.A., McCarthy J., and Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?. J Cell Sci 121 (2008) 925-932
28. Giannopoulos K., Mertens D., Buhler A., et al. The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 23 (2009) 519-527
29. Zlobec I., Terracciano L., Tornillo L., et al. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut 57 (2008) 1413-1419
30. Tzankov A., Went P., Zimpfer A., and Dirnhofer S. Tissue microarray technology: principles, pitfalls and perspectives-lessons learned from hematological malignancies. Exp Gerontol 40 (2005) 737-744
31. Atkins D., Reiffen K.A., Tegtmeier C.L., Winther H., Bonato M.S., and Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52 (2004) 893-901
32. Zlobec I., Terracciano L., Jass J.R., and Lugli A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 451 (2007) 763-769
33. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. In press.
34. Tzankov A., Went P., and Dirnhofer S. Prognostic significance of in situ phenotypic marker expression in diffuse large B-cell lymphomas. Biomarker Insights 2 (2007) 403-417
35. Tzankov A., Meier C., Hirschmann P., Went P., Pileri S.A., and Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93 (2008) 193-200
36. Tzankov A., Gschwendtner A., Augustin F., et al. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 12 (2006) 2125-2132
37. Obermann E.C., Csato M., Dirnhofer S., and Tzankov A. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol 62 (2009) 754-756
38. Kremmidiotis G., Ridings J., Hicks M., et al. Heterogeneity of CD44 expression among human B-cell subpopulations. Tissue Antigens 51 (1998) 232-241
39. Mythreye K., and Blobe G.C. Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal 21 (2009) 1548-1558
40. Eser B., Sari I., Canoz O., et al. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma. Am J Hematol 81 (2006) 307-314
41. Abramson J.S., and Shipp M.A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106 (2005) 1164-1174
42. Trowbridge I.S., Lesley J., Schulte R., Hyman R., and Trotter J. Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues. Immunogenetics 15 (1982) 299-312
43. Mackay C.R., Terpe H.J., Stauder R., Marston W.L., Stark H., and Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 124 (1994) 71-82